AstraZeneca has introduced 19 abstracts (abstract of the document), including 10 oral presentations and the last five presentations, at the Congress of the European Society of Cardiology (ESC), carried out from 25 to 28 August 2023. Among the data contained in this document, opportunities to increase heart failure management (CI), and AstraZeneca leadership in association with chronic disease.

In addition, among the abstracts there are sub-analyses DELIVERY trial, it is important to report medical guideline updates. In particular, the new data breakthrough relates to DELIVER and combined analysis DAPAHFwho evaluated the efficacy of Forxiga (dapgliflozin) versus placebo in heart failure patients. The findings show a marked improvement in risk of cardiovascular events in patients with impaired renal function, further strengthening the relationship between HF and kidney disease.

“We are proud of this ongoing evidence which changed the practice of the dapagliflozin trial, reported an update recognizing SGLT2 inhibitors as the first and only therapy in heart failure with a class 1A 6 recommendation,” he explained. Ruud DoberExecutive Vice President and President of AstraZeneca’s Biopharmaceutical Unit.

“Our data presented at ESC 2023 reinforces how complex and interconnected heart and lung diseases are; Disease in one organ system negatively affects other organ systems.

On the other hand, even though they are on the same development path, they present new data a Sub-analysis of the GIVE trialwho demonstrated the effect of dapagliflozin in HF patients with preserved ejection fraction (EPF) and chronic obstructive pulmonary disease (COPD), a common comorbidity associated with a poorer outcome.

“Our data is presented in ESC 2023 reinforces how complex cardiorenal and cardiopulmonary disease can be interconnected; disease in one organ system that negatively affects other organ systems. By understanding the linkages, we will be able to detect, diagnose and treat people earlier and more effectively for better outcomes,” said Dobber.

In addition to this important update, the company has also presented at ESC 2023: An up-to-date study of the justification and innovative design of randomized DAPA-MI trial; a recent study supported by researchers, which is the first study to demonstrate data on efficacy and safety initial use of dapgliflozin; recent presentation on using artificial intelligence to automate analysis transthoracic echocardiography laptops; real world data EVOLUTION HF in England; and investing in new approaches with first scientific results from Phase I trials demonstrating safety, tolerability, and pharmacokinetics AZD5462.